The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Syst Biol Reprod Med. 2023 Oct;69(5):333-346. doi: 10.1080/19396368.2023.2241600. Epub 2023 Aug 14.
Oligoasthenozoospermia is becoming a serious problem, but effective prevention or treatment is lacking. Hyperoside, one of the main active ingredients in traditional Chinese medicine, may be effective in the treatment of oligoasthenozoospermia. In this study, we used cyclophosphamide (CTX: 50 mg/kg) to establish a mouse model of Oligoasthenozoospermia to investigate the therapeutic effect of hyperoside (30 mg/kg) on CTX-induced oligoasthenozoospermia. All mice were divided into four groups: blank control group (Control), treatment control group (Hyp), disease group (CTX) and treatment group (CTX + H). Mice body weight, testicular weight, sperm parameters and testicular histology were used to assess the reproductive capacity of mice and to explore the underlying mechanism of hyperoside in the treatment of oligoasthenozoospermia by assessing hormone levels, protein levels of molecules related to hormone synthesis and transcript levels of important genes related to spermatogenesis. Treatment with hyperoside significantly improved sperm density, sperm viability and testicular function compared to untreated oligoasthenozoospermia mice. In mechanism, treatment with hyperoside resulted in significant improvement in pathological changes in spermatogenic tubules, with an increase in testosterone production, and upregulations of Protein Kinase CAMP-Activated Catalytic Subunit Beta (PRKACB), Steroidogenic Acute Regulatory Protein (STAR), and Cytochrome P450 Family 17 Subfamily A Member 1 (CYP17A1) for testosterone production. Hyperoside also promoted the cell cycle of germ cells and up-regulated meiosis and spermatogenesis-related genes, including DNA Meiotic Recombinase 1 (Dmc1), Ataxia telangiectasia mutated (Atm) and RAD21 Cohesin Complex Component (Rad21). In conclusion, hyperoside exerted protective effects on oligoasthenozoospermia mice by regulating testosterone production, meiosis and sperm maturation of germ cells.
少弱精子症正成为一个严重的问题，但缺乏有效的预防或治疗措施。淫羊藿苷是中药的主要活性成分之一，可能对少弱精子症的治疗有效。在这项研究中，我们使用环磷酰胺（CTX：50mg/kg）建立了少弱精子症小鼠模型，以研究淫羊藿苷（30mg/kg）对 CTX 诱导的少弱精子症的治疗作用。所有小鼠分为 4 组：空白对照组（Control）、治疗对照组（Hyp）、疾病组（CTX）和治疗组（CTX+H）。通过评估体重、睾丸重量、精子参数和睾丸组织学，来评估小鼠的生殖能力，并通过评估激素水平、与激素合成相关分子的蛋白水平以及与精子发生相关的重要基因的转录水平，来探讨淫羊藿苷治疗少弱精子症的潜在机制。与未治疗的少弱精子症小鼠相比，淫羊藿苷治疗显著改善了精子密度、精子活力和睾丸功能。在机制上，淫羊藿苷治疗导致生精小管的病理变化显著改善，睾丸酮生成增加，蛋白激酶 A 环核苷酸激活催化亚基β（PRKACB）、类固醇急性调节蛋白（STAR）和细胞色素 P450 家族 17 亚家族 A 成员 1（CYP17A1）等与睾丸酮生成相关的分子表达上调。淫羊藿苷还促进了生殖细胞的细胞周期，并上调了减数分裂和精子发生相关基因，包括 DNA 减数重组酶 1（Dmc1）、共济失调毛细血管扩张突变基因（Atm）和 RAD21 黏合复合物成分（Rad21）。总之，淫羊藿苷通过调节睾丸酮生成、生殖细胞减数分裂和精子成熟，对少弱精子症小鼠发挥了保护作用。
